Cardiovascular disease is a leading cause of death and disability in the United States.
National programs, such as the National Cardiovascular Data Registry, facilitate …

Appropriate interpretation of changes in markers of kidney function is essential during the
treatment of acute and chronic heart failure. Historically, kidney function was primarily …

Heart failure (HF) and end-stage kidney disease (ESKD) frequently coexist; 1 comorbidity
worsens the prognosis of the other. HF is responsible for almost half the deaths of patients …

Chronic kidney disease (CKD) is increasingly prevalent in patients with heart failure (HF)
and HF is one of the leading causes of hospitalisation, morbidity and mortality in patients …

Heart failure and chronic kidney disease are common and clinically important conditions that
regularly coexist. Electrophysiologic changes of advanced heart failure often result in …

Background: A prolonged PR interval is common among cardiac resynchronization therapy
(CRT) candidates; however, the association between PR interval and outcomes is unclear …

Heart failure with reduced ejection fraction (HFrEF) impacts approximately 20% of dialysis
patients and is associated with high mortality rates. Key issues discussed in this review of …

Non-pharmacological therapies play an essential role in the management of heart failure,
complementing pharmacological treatments to mitigate disease progression and improve …

Background Although cardiac resynchronization therapy (CRT) is effective for some patients
with heart failure and a reduced left ventricular ejection fraction (HFrEF), evidence gaps …

Aims Patients with impaired renal function were shown to have an attenuated benefit from
implantable cardioverter-defibrillator. However, there are limited data on the competing risk …